Targeting the PI3K Signaling Pathway in Cancer

Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Humans
  • MAP Kinase Kinase Kinases
  • Neoplasms / drug therapy*
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphoinositide-3 Kinase Inhibitors*
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • MAP Kinase Kinase Kinases